However, as observed in other IL-6 mediated disease such as Castelman's disease and smoldering multiple myeloma [40], [41], a variable percentage of these patients (from 40 to 87% according to the different studies) also shows a dramatic and persistent response to anti-IL-1 blockade, with the rest of SoJIA patients being resistant to such a treatment [23], [42], [43],. This evidence concerns the gene IL1B and plasma cell myeloma.